Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International, plc chief strategy officer Eben Tessari exercised Restricted Share Units into common shares and had shares withheld for taxes. On April 7, 2026, 2,726 RSUs were converted into 2,726 Class A Ordinary Shares. Of these, 846 shares at $48.94 per share were withheld to satisfy tax obligations, leaving Tessari with 23,130 Class A Ordinary Shares held directly. Each RSU represents a right to receive one Class A Ordinary Share and the RSU grant vests in four equal annual installments starting on April 7, 2023, over a four-year period.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Each RSU converts into one share and is part of a grant that vests in four equal annual installments starting April 7, 2022.
To cover tax obligations from this vesting, 1,303 Class A Ordinary Shares were withheld at a price of $48.94 per share, rather than sold in the open market. After these compensation-related transactions, Ragosa directly holds 16,154 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc Chairman & CEO Sanj K. Patel reported multiple equity transactions in the company’s Class A Ordinary Shares. On April 6, 2026, he exercised options for 7,278 shares at $10.36 per share and sold 7,278 shares at a weighted average price of about $50.01 in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.
On April 7, 2026, 9,991 Restricted Share Units converted into the same number of Class A Ordinary Shares, credited to The Patel Family Irrevocable Trust of 2025. Of these, 4,831 shares were withheld at $48.94 per share to cover tax obligations, leaving 76,174 shares in that trust. Additional indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Kiniksa Pharmaceuticals’ chief medical officer John F. Paolini exercised 2,497 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Of these shares, 1,208 were withheld at $48.94 per share to cover tax obligations, and he now directly holds 65,623 Class A Ordinary Shares. The RSUs come from a grant that vests over four years, with 25% vesting on each anniversary of the April 7, 2022 grant date.
Kiniksa Pharmaceuticals International, plc chief operating officer Ross Moat reported a series of equity transactions involving Class A Ordinary Shares. On April 7, 2026, he exercised 2,477 Restricted Share Units, receiving an equal number of Class A Ordinary Shares as the RSUs converted one-for-one.
On the same date, 774 shares were disposed of at $48.94 per share to cover tax obligations related to the equity award, a non-market tax-withholding transaction. On April 6, 2026, he completed an open‑market sale of 2,367 Class A Ordinary Shares at $48.58 per share under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, he directly holds 12,029 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna exercised restricted share units and had shares withheld for taxes. On this date, 3,932 Restricted Share Units converted into 3,932 Class A Ordinary Shares. Of these, 1,666 shares were disposed of to cover tax obligations at a price of $48.94 per share, a non-market tax-withholding transaction. After these compensation-related events, Megna directly held 34,043 Class A Ordinary Shares. The RSUs vest over four years, with 25% vesting on each yearly anniversary of the April 7, 2022 grant date.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart exercised stock options and sold the resulting shares in a planned transaction. On April 6, 2026, he exercised options for 6,901 Class A Ordinary Shares at $14.33 per share, then sold the same 6,901 shares at a weighted average price around $50.00 under a pre-arranged Rule 10b5-1 trading plan. His direct ownership of Class A Ordinary Shares remained at 12,546 shares after the transactions, while his remaining option position decreased by the exercised amount.
Kiniksa Pharmaceuticals (KNSA) reports a Form 144 notice for the intended sale of 20,000 Class A ordinary shares on 04/06/2026, executed as a broker payment for a cashless exercise. The filing also lists recent open-market dispositions by Barry D. Quart, including 12,528 shares on 02/03/2026 and 2,690 shares on 02/12/2026.
Kiniksa Pharmaceuticals submitted a Form 144 reporting 219,591 Class A ordinary shares related to an employee stock option exercise on 04/06/2026. The filing lists $10,979,550.00 in an adjacent field and a reference number of 45,900,637, with broker handling by Charles Schwab & Co.
Kiniksa Pharmaceuticals (KNSA) submitted a Form 144 notice relating to the proposed sale of 2,367 Class A ordinary shares, reported in connection with a restricted stock lapse dated 04/01/2026. The filing lists Charles Schwab & Co., Inc. as the broker and references NASDAQ. A numeric line shows 45,900,637, which appears alongside other securities data in the excerpt.